Brought to you by 
Arrowhead Research licenses Shire rights to homing peptide platform
07 Jan 2013
Executive Summary
Rare disease drug developer Shire PLC has received a worldwide license to use Arrowhead Research Corp.’s (has compounds in development for cancer and metabolic and infectious diseases) human-derived homing peptide platform to develop and commercialize targeted peptide-drug conjugates (PDCs) with its own therapeutic payloads.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arrowhead Research licenses Shire rights to homing peptide platform
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice